FDA Issues New Draft Guidance on Clinical Trial Meta-Analysis

Drug Industry Daily
The FDA may accept safety analyses drawn and projected out from pooled clinical trial data as long as sponsors have carefully planned their evaluations and are willing to show their work, the agency says in new draft guidance issued Tuesday.

To View This Article:


Subscribe To Drug Industry Daily